Stony Brook Heart Institute’s Center for Advanced Lipid Management has achieved a historic global milestone, becoming the first center in the world to administer a commercial dose of plozasiran, the ...

Sean Ryder, professor at UMass Chan Medical School, has written a book to delve the mysteries of ribonucleic acid as a tool to fight diseases. Messenger ribonucleic acid, or mRNA, is in the public ...

X-linked retinoschisis gene replacement therapy, aiming to improve retinal architecture and visual function in young male ...

Discover how a tiny RNA molecule serves as a molecular switch in viral infections, providing insights into phage biology.

Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the appointment of Adrian Bot, M.D.

As antibiotic-resistant infections rise and are projected to cause up to 10 million deaths per year by 2050, scientists are ...

Backed by a handful of prominent investors including the Gates Foundation, the startup is pursuing an approach it believes ...

As RNA therapeutics evolve far beyond their vaccine origins, a new generation of scientists and manufacturers is rethinking how to produce these complex medicines safely, efficiently, and at scale.

The FDA approved plozasiran (Redemplo) for the reduction of triglycerides in people with familial chylomicronemia syndrome (FCS), the agency announced. The small interfering RNA (siRNA) therapy, ...

Two complementary studies led by researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), have demonstrated a new RNA-based therapeutic strategy that ...

Almost a year after buying Kate Therapeutics, Novartis has scooped up another San Diego-based muscle dystrophy biotech in one of the biggest acquisitions of 2025 so far. The Swiss pharma is paying $12 ...

A gene therapy injected into patients’ brains slowed progression of the disease by 75 percent, preliminary findings reported. By Dana G. Smith Preliminary results from a small clinical trial to treat ...